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Molecular Alterations Critical to the
Development of Arteriosclerotic Plaques:
A Role for Environmental Agents
by Arthur Penn*
Cardiovascular disease (CVD) is the single greatest cause ofdeath in the United States and in Western Eu-
rope. There is strong epidemiologic evidence for an interaction ofenvironmental and genetic factors in the
development ofclinically significant episodes ofCVD. However, the specific contributions ofeach ofthese
components to the onset and development ofCVD remain unclear. According to the monoclonal hypothesis,
arteriosclerotic plaques, theprincipal lesions associated with CVD, are monoclonal inorigin and can be con-
sidered benign smooth muscle cells tumors ofthe artery wall. It follows that somatic cell alterations, possi-
bly brought about by chemical mutagens or viruses, may play critical roles in plaque formation.
During the past decade, evidence has been presented from a number oflaboratories, including ours, that
in animal model systems, both viruses and chemical carcinogens can play akey role in the appearance and
development ofarteriosclerotic plaques. We have recently provided evidence consistefit with the view that so-
matic cell alterations are critical to plaque development in man: DNA from human arteriosclerotic plaques
transforms cells in vitro and injection ofthese transformed cells into nude mice results in tumor formation.
Thus, plaque DNA behaves similarly to tumor DNA under defined assay conditions.
Introduction
Duringthe past decade, there have beenprofound shifts
in the types ofquestions asked and the experimental ap-
proaches adopted by investigators in the field ofenviron-
mental health. In part, this is due to the growing recog-
nition that a very large number of exogenous agents
acting singly, together, or synergistically can have pro-
found effects upon the etiology and/or development of a
wider variety of diseases and illnesses than had previ-
ously thought to be the case. This is also partly due to tre-
mendous technical advances. Analytical instrumentation
and methodologies have progressed to the point that the
molecular mechanisms that underlie the responses of
cells, tissues, and organisms to environmental stressors
can now be investigated. In the discussion thatfollows, re-
cent findings will be considered that implicate environ-
mental agents in the etiology ofarteriosclerotic plaques.
Additionally, evidence will be summarized that similar
molecular mechanisms may underlie critical events in the
development of plaques and tumors.
In cancer studies, it has been well accepted for many
years that at least two distinct cellular events (hits) are
necessary to effect cell transformation in vitro or carcino-
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genesis in vivo. If one of these events is derived en-
dogenously (a germ line mutation or a spontaneous so-
matic mutation are two possibilities), then an environ-
mental insult resulting in a second complementary mu-
tation (e.g., activation ofthe ras oncogene) may be suffi-
cient to trigger transformation. The role ofenvironmen-
tal agents in oncogene activation is considered by other
contributors to this volume.
Although there is much discussion in this volume ofcan-
cer and the role of environmental agents in its develop-
ment, the leading cause of death in most Western coun-
tries, including the United States, is not cancer, but
rather, cardiovascular disease (CVD). Environmental fac-
tors (e.g., cigarette smoke and agents that elevate blood
pressure) have been associated with the development of
clinically significant episodes ofCVD. However, evidence
linkingthese factors to CVD in a causal way, let alone the
demonstration thatthese factors are directly involved in
themoleculareventswhichunderlie developmentofCVD,
are lacking.
The principallesion characteristic ofCVD is the arteri-
oscleroticplaque. The plaque consists ofcellularelements
[primarily smooth muscle cells (SMC)but also some mac-
rophages] andformed elements (includinglipid deposits,
collagen, elastin, and glycosaminoglycans). In advanced
plaques, necrosis and calcification may occur. Critical to
the development of plaques is the proliferation of SMC
within the intimal region of the artery wall.A. PENN
Results and Discussion
Injury versus Monoclonality
The traditional view is that the stimulus to SMC
proliferation is injury (1), eg., by hemodynamic factors or
bloodborne agents. Although there is considerable cir-
cumstantial evidence to support the contention that these
factorsplay arole inplaqueformation, the evidence isless
compelling that these factors are the primary causes of
arterial SMC proliferation in vivo and the subsequent
plaque development. Ifthe plaques arise as a response to
injury, then the plaques should bepolyclonal as are other
healingwounds. That is, the cells that occupy the wound
site and repopulate it duringthe healing process are der-
ived from many different cells, even ifonly one cell type
is involved.
An alternative to the injury-plaque scenario was pro-
vided by isozyme studies on plaques obtained from au-
topsy samples. Evidence was obtained that human arteri-
osclerotic plaques are monoclonal in origin (2). An
argument canbe made that apparentmonoclonality could
arise because ofstrong selection pressure favoring asub-
population ofcells that appear in response towound heal-
ing. However, a simpler, more straightforward, albeit con-
troversial, conclusion presents itself, namely, the
monoclonality is evidence that the plaques are benign
SMC tumors ofthe artery wall. The monoclonal hypothe-
sis, as it came to be known, provided newinsight into the
study ofplaque etiology and in the process established a
role for environmental medicine in these investigations.
Environmental agents that had been implicated previ-
ously in cell transformation and tumorigenesis now be-
came candidates for involvement in arteriosclerosis as
well. An earlyprediction that arose from themonoclonal
hypothesis was that viruses and chemical mutagens
would be expected to play critical roles in plaque forma-
tion and development, just as they do in tumorigenesis.
Viruses and Mutagens in Plaque
Development
The earliest attempt at verifying this prediction came
from Roy Albert and his co-workers at NYU's Depart-
ment ofEnvironmental Medicine. Weeklyinjections ofthe
polycyclic aromatic hydrocarbon (PAH) carcinogens
7,12-dimethylbenz[a]anthracene (DMBA) or benzo[a]py-
rene (BaP) resulted inlarge, proliferating plaques in the
abdominal aortain cockerels (3). Plaques increased in size
in a dose-dependent fashion (4), and even a single injec-
tion at 5 weeks of age was sufficient to cause a marked
increase in thymidine-labeling index of plaque SMC (5)
within 1 week. Enzymes ofthe cytochrome P-450 system
have been identified inboth the adultartery wall(6,7) and
infetal aortic SMC (8). The analogy betweenplaques and
benign tumors was strengthened by a recent demonstra-
tion that DMBA and methoxamine, administered in an
initiation-promotion protocol, resulted in the appearance
of microscopic, focal thoracic aorta plaques in cockerels
(9).
The PAH effect is more complex than it was originally
thought to be on at least two accounts. First, some non-
carcinogenic PAHs also stimulate plaque development
(Penn, manuscript inpreparation). Second, extensive tem-
poral studies(5), aswell aslight and electronmicroscopic
(10) investigations, revealed that ratherthan causingnew
plaques to appear, theprincipal effect ofPAH administra-
tion, atleast in cockerels, isto accelerate the development
ofpreexisting aortic plaques. For example, aortic plaques
in 8-week-old cockerels that received four weekly injec-
tions ofDMBA are the same size as plaques in 20-week-
old control animals (11).
The second prediction arising from the monoclonal
hypothesis, thatvirusesmightplayacriticalroleinplaque
formation, wasborne out as well. Single injections ofthe
oncogenic avian herpes virus, Marek's disease virus, into
4-day-old cockerels yielded focal microscopic plaques in
the thoracic aorta(12,13). Apossiblelinkwasrecently in-
ferredbetween viralinfection and alterations inlipidme-
tabolism, the latter being more traditionally associated
than the former with the development ofCVD. Aortas of
cockerels infectedinvivo with Marek's disease virus and
arterial SMC infected in vitro with this virus both dis-
played altered synthesis and accumulation ofcholesterol
esters (14,15). There is one report that herpes virus ge-
nomes havebeen identified in humanarterywall andpos-
sibly even in plaques (16). However, no strong evidence
yet exists that viral infection is an etiologic agent in
plaque formation in man.
Thefactthat viruses and chemical carcinogens canplay
akeyrole in experimental arteriosclerosis is interesting,
but by itselfultimatelyunsatisfying. From amedical per-
spective, it is vital to show that these agents can play a
role in development of clinically significant arterio-
scleroticplaques. Just as importantly would be the dem-
onstration of a viable molecular mechanism to explain
how viruses and mutagens could play a critical and pos-
siblyirreversible role inplaqueformation. Thiswouldalso
help to confirm the putative relationship between plaques
and tumors.
Somatic Cell Alterations and Plaque
Development
Molecular biology techniques developed over the past
decade have permitted direct demonstration that specific
types ofgenetic alteration are characteristic ofcell trans-
formation and tumor development. In ourlaboratory, we
have adapted these procedures to studies of human
plaques. Specifically, we have demonstrated via gene
transfer procedures that human plaque DNA is capable
oftransforming NIH 3T3 cells in culture (17). Following
injection into nude mice, these transformants consistently
give rise topanels ofslowlygrowingtumors. The identity
of the plaque-derived transforming gene(s) is not yet
known. Itisimportant torecognize thatthe NIH 3T3 cell
gene transfer assay that we have employed is most effec-
tive atidentifyingalimited range ofdominanttransform-
ing genes. Recent evidence has demonstrated that as
other assays ofincreasing sensitivity are developed, the
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chances increase of more readily identifying transform-
ing genes (18,19). We are currently investigating the ef-
fectiveness ofthese assayswithplaque DNAs ofbothhu-
man and animal origin.
A different approach to the question ofgenetic altera-
tions inplaques or in cells thatmight becomeplaques has
recently been described. Mildly elevated levels of c-sis
mRNA have beenfound in human atherosclerotic plaques
compared to the levels found in normal artery (20); c-sis
is the cellular homologue ofthe sis oncogene. The gene
product inboth cases is essentially identical to theP-chain
ofthe growth factor PDGF. The association ofplatelets
with areas ofarterial wall injury, the subsequent release
ofplatelet factors, presumably including PDGF, and the
ensuingproliferation ofarterial wall SMC have beenwell
documented in experimental systems. Whether similar
events are relevant to clinically significant plaque devel-
opment remains to be determined.
Prognosis
Elevated levels of serum cholesterol, high blood pres-
sure, and cigarette smoking are the three leading in-
dependent risk factors for the development of CVD.
Epidemiological evidence indicates that in an individual
with two or more of these risk factors, the likelihood of
suffering a CVD episode increases multiplicatively (21).
However, no causal relationship has been identified be-
tween these factors and CVD. In addition, many people
suffering from CVD (> 40%) display none of these risk
factors. The possibility is strong that an interplay ofen-
vironmental agents with genetic factors is necessary in
many cases for CVD to manifest itself in a clinically
meaningful way.
Carcinogenesis studies ofthe past fewyears have iden-
tified specific environmental agents (PAHs, alkylating
agents, X-rays, even 03) that are capable of activating
transforminggenes. In some cases, the mechanism ofac-
tion(e.g., induction ofamutation in codon 12 or codon 61
ofthe ras gene) has beenidentified. Once the transform-
ing gene(s) present in arteriosclerotic plaques is identi-
fied, it will become feasible to ask how specific environ-
mental agents interact with this gene to activate it.
The existence ofan inexpensive animal model exhibit-
ing rapid plaque development, the cockerel, allows us to
ask at whatpoint during orprior to plaque development
is the transforming gene activated. The human samples
studies so far are from middle-aged to elderly patients
with severe CVD. Thus, it is impossible to correlate acti-
vation ofa transforming gene with a stage ofplaque de-
velopment in these samples.
Studies of human fatty streaks, a precursor lesion to
plaques, indicate that there are subpopulations with
monoclonal characteristics (22). Fatty streaks have also
been identified in animal model systems, including mon-
keys, pigs, andrabbits. Resultsfrom ourlaboratory sum-
marized earlierindicate that in cockerels, the effect ofcar-
cinogens is to accelerate plaque development. The
monoclonal fatty steaks may represent a population of
already-mutated cells that require a second mutagenic
event, eg., by an environmental agent, in orderto develop
into a fully developed plaque. This can be tested both in
vitro and in vivo.
Finally, the tumors that arise inmice following injection
of plaque DNA-transformed cells develop much more
slowly than do most tumors arisingfollowing injection of
cells containing activated oncogenes (7-16 weeks for
plaque DNA associated tumors versus < 2 weeks for ac-
tivated ms-associated tumors). As yet, no reasonable ex-
planationhasbeenpresentedforwhyinplaque-associated
tumorsthere is such alonglatentperiod, aswell as an ex-
tended period of development once the tumors become
visible These questions areespeciallyinterestingbecause
there are no other clear-cut differences between plaque-
associated tumors and ras-associated tumors.
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